Proposed Pharmacological Treatments for COVID-19: Previously Confirmed Drugs

Fatemeh Bahoosh Feyzabadi, A. Nikjoo, Mohammad Reza Lagzian, Hessamedin Babaei, Melika Nasehi
{"title":"Proposed Pharmacological Treatments for COVID-19: Previously Confirmed Drugs","authors":"Fatemeh Bahoosh Feyzabadi, A. Nikjoo, Mohammad Reza Lagzian, Hessamedin Babaei, Melika Nasehi","doi":"10.18502/pbr.v8i2.11024","DOIUrl":null,"url":null,"abstract":"Background: The outbreak of severe acute respiratory syndrome coronavirus-2, also called ‘coronavirus disease 2019’ (COVID-19), first appeared in December 2019 in Wuhan, China. COVID-19 is caused by an enveloped single-stranded RNA virus, which has affected more than 14 million people around the world and caused a high rate of mortality. It is notable that discovering new drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is time-consuming. Therefore, reviewing drugs, which have been previously designed for other purposes can be helpful and effective. \nObjectives: Studying the effects of previously approved drugs is important; thus, in this article, we reviewed studies on proposed drugs against COVID-19. \nMethods: The articles and information were collected from Google Scholar, ScienceDirect, and Scopus databases. We did our research based on keywords, like “therapeutics”, “pharmacology”, “Coronavirus”, “COVID-19”, “SARS”, and “MERS-CoV”. We also applied some filters, such as title/abstract, and ignored factors that could lead to bias and selective selection. \nResults: There is currently no cure for coronavirus, and most treatments have been effective to relieve symptoms. The treatment methods and drugs addressed in this article are chosen either from previous drugs against MERS and SARS, drugs that disrupt the life cycle of the coronavirus, or drugs that have been reviewed in retrospective studies and clinical trials. \nConclusion: Prevention and treatment of COVID-19 remain a challenge, in particular for coronavirus and the treatments based on boosting the immune system and preventing virus replication. Epidemiological studies have shown that COVID-19 and SARS-COV transmission are relatively similar. This can help to select the appropriate drug. Thus, anti-inflammatory and antiviral drugs, such as remdesivir are used. Antimalarial drugs, such as hydroxychloroquine (HCQ) and chloroquine (CQ) along with estrogen receptor inhibitors, such as toremifene citrate, which has shown effective results against SARS and MERS, can influence the treatment process. However, more clinical trials are needed to determine the efficacy and side effects of drugs.","PeriodicalId":6323,"journal":{"name":"2005 Asian Conference on Sensors and the International Conference on New Techniques in Pharmaceutical and Biomedical Research","volume":"43 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"2005 Asian Conference on Sensors and the International Conference on New Techniques in Pharmaceutical and Biomedical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/pbr.v8i2.11024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The outbreak of severe acute respiratory syndrome coronavirus-2, also called ‘coronavirus disease 2019’ (COVID-19), first appeared in December 2019 in Wuhan, China. COVID-19 is caused by an enveloped single-stranded RNA virus, which has affected more than 14 million people around the world and caused a high rate of mortality. It is notable that discovering new drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is time-consuming. Therefore, reviewing drugs, which have been previously designed for other purposes can be helpful and effective. Objectives: Studying the effects of previously approved drugs is important; thus, in this article, we reviewed studies on proposed drugs against COVID-19. Methods: The articles and information were collected from Google Scholar, ScienceDirect, and Scopus databases. We did our research based on keywords, like “therapeutics”, “pharmacology”, “Coronavirus”, “COVID-19”, “SARS”, and “MERS-CoV”. We also applied some filters, such as title/abstract, and ignored factors that could lead to bias and selective selection. Results: There is currently no cure for coronavirus, and most treatments have been effective to relieve symptoms. The treatment methods and drugs addressed in this article are chosen either from previous drugs against MERS and SARS, drugs that disrupt the life cycle of the coronavirus, or drugs that have been reviewed in retrospective studies and clinical trials. Conclusion: Prevention and treatment of COVID-19 remain a challenge, in particular for coronavirus and the treatments based on boosting the immune system and preventing virus replication. Epidemiological studies have shown that COVID-19 and SARS-COV transmission are relatively similar. This can help to select the appropriate drug. Thus, anti-inflammatory and antiviral drugs, such as remdesivir are used. Antimalarial drugs, such as hydroxychloroquine (HCQ) and chloroquine (CQ) along with estrogen receptor inhibitors, such as toremifene citrate, which has shown effective results against SARS and MERS, can influence the treatment process. However, more clinical trials are needed to determine the efficacy and side effects of drugs.
建议的COVID-19药物治疗:先前确认的药物
背景:2019年12月,中国武汉首次爆发了严重急性呼吸综合征冠状病毒-2,也称为“冠状病毒病2019”(COVID-19)。COVID-19是由一种包膜单链RNA病毒引起的,该病毒已影响到全球1400多万人,并造成了很高的死亡率。值得注意的是,开发针对严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)的新药和疫苗非常耗时。因此,回顾以前为其他目的而设计的药物可能是有帮助和有效的。目的:研究先前批准的药物的作用是重要的;因此,在本文中,我们回顾了针对COVID-19的拟议药物的研究。方法:文献资料来源于Google Scholar、ScienceDirect和Scopus数据库。我们根据“治疗学”、“药理学”、“冠状病毒”、“COVID-19”、“SARS”和“MERS-CoV”等关键词进行了研究。我们还应用了一些过滤器,如标题/摘要,并忽略了可能导致偏见和选择性选择的因素。结果:目前还没有治愈冠状病毒的方法,大多数治疗方法都能有效缓解症状。本文所讨论的治疗方法和药物要么是以往针对中东呼吸综合征和SARS的药物,要么是破坏冠状病毒生命周期的药物,要么是在回顾性研究和临床试验中经过审查的药物。结论:COVID-19的预防和治疗仍然是一个挑战,特别是在冠状病毒和基于增强免疫系统和防止病毒复制的治疗方面。流行病学研究表明,COVID-19和SARS-COV的传播方式相对相似。这有助于选择合适的药物。因此,使用抗炎和抗病毒药物,如瑞德西韦。抗疟疾药物,如羟氯喹(HCQ)和氯喹(CQ),以及雌激素受体抑制剂,如柠檬酸托瑞米芬,已经显示出对SARS和MERS有效的效果,可以影响治疗过程。然而,需要更多的临床试验来确定药物的疗效和副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信